SLC22A6抗体

+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane: Human fetal kidney tissue, Primary antibody: P04403(SLC22A6 Antibody) at dilution 1/600, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 3 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P04403(SLC22A6 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P04403(SLC22A6 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

The SLC22A6 antibody is a research tool designed to detect and study the solute carrier family 22 member 6 (SLC22A6), also known as organic anion transporter 1 (OAT1). OAT1. encoded by the *SLC22A6* gene, is a transmembrane protein predominantly expressed in the kidneys, specifically in the basolateral membrane of proximal tubule cells. It plays a critical role in the renal excretion of endogenous organic anions, including metabolites, toxins, and anionic drugs (e.g., antivirals, antibiotics, and diuretics). By mediating substrate uptake from the blood into tubular cells, OAT1 facilitates their subsequent secretion into urine, influencing drug pharmacokinetics and toxicity.

The SLC22A6 antibody is widely used in biomedical research to investigate OAT1 expression, localization, and function under physiological or pathological conditions, such as kidney disease, drug-induced nephrotoxicity, or metabolic disorders. It is commonly applied in techniques like Western blotting, immunohistochemistry, and immunofluorescence. Antibody specificity varies depending on epitope targets (e.g., N-terminal or C-terminal regions) and validation in relevant cell or tissue models. Research involving this antibody contributes to understanding drug-drug interactions, renal transport mechanisms, and genetic variants affecting drug response. Its utility extends to preclinical studies aiming to optimize therapeutic regimens or mitigate adverse effects linked to OAT1 activity.